GSK マネジメント GSKの CEO はEmma Walmsleyで、 Apr2017年に任命され、 の在任期間は 7.58年です。 の年間総報酬は£ 12.72Mで、 10.3%給与と89.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.04%を直接所有しており、その価値は$ 28.17M 。経営陣と取締役会の平均在任期間はそれぞれ6年と3.2年です。
主要情報 CEO給与比率 10.3% CEO在任期間 7.6yrs CEOの所有権 0.04% 経営陣の平均在職期間 6yrs 取締役会の平均在任期間 3.2yrs
経営陣の近況 Gsk plc Announces Board Committee Changes May 09
GSK plc, Annual General Meeting, May 08, 2024 Mar 26 GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024 Mar 09
すべての更新を表示
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy' Oct 26
GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk Oct 24
GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents Oct 16
GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2 Oct 14 Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine Oct 08 Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion Sep 24
GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell Sep 19
GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX Sep 18
GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme Sep 13
GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon Sep 12
GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial Sep 11
GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease Aug 29 GSK plc Announces Zantac (Ranitidine) Litigation Update
GSK's Q2 Success Amid Challenges: What Investors Need To Know Aug 26 GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227 Aug 20
Gsk plc Announces Zantac (Ranitidine) Litigation Update Aug 16
GSK plc Announces Zantac (Ranitidine) Litigation Update Aug 06
GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit Aug 02
GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade) Jul 31 GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024 Jul 31
GSK plc Announces Blenrep EMA Filing Acceptance Jul 22
GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season Jul 12
GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer Jun 18
GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy Jun 13
GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million. Jun 08 GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin Jun 05
GSK plc Provides Litigation Update May 25
GSK Breathes New Life Into Asthma Treatment With Depemokimab May 22 An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion. May 18
GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon Gsk plc Announces Board Committee Changes May 09
GSK plc to Report Q2, 2024 Results on Jul 31, 2024 May 03 GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli Apr 24
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate Apr 16
GSK plc, Annual General Meeting, May 08, 2024 Mar 26 GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024 Mar 09
GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin) Mar 08
GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders. Feb 15
GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B Feb 14
Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over Feb 07 Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial
GSK plc to Report Q1, 2024 Results on May 01, 2024 Feb 02
CEO報酬分析 GSK の収益と比較して、Emma Walmsley の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Sep 30 2024 n/a n/a UK£3b
Jun 30 2024 n/a n/a UK£4b
Mar 31 2024 n/a n/a UK£4b
Dec 31 2023 UK£13m UK£1m UK£5b
Sep 30 2023 n/a n/a UK£6b
Jun 30 2023 n/a n/a UK£5b
Mar 31 2023 n/a n/a UK£4b
Dec 31 2022 UK£8m UK£1m UK£4b
Sep 30 2022 n/a n/a UK£3b
Jun 30 2022 n/a n/a UK£4b
Mar 31 2022 n/a n/a UK£4b
Dec 31 2021 UK£8m UK£1m UK£3b
Sep 30 2021 n/a n/a UK£4b
Jun 30 2021 n/a n/a UK£4b
Mar 31 2021 n/a n/a UK£5b
Dec 31 2020 UK£7m UK£1m UK£5b
Sep 30 2020 n/a n/a UK£6b
Jun 30 2020 n/a n/a UK£7b
Mar 31 2020 n/a n/a UK£5b
Dec 31 2019 UK£8m UK£1m UK£5b
Sep 30 2019 n/a n/a UK£5b
Jun 30 2019 n/a n/a UK£4b
Mar 31 2019 n/a n/a UK£4b
Dec 31 2018 UK£6m UK£1m UK£4b
Sep 30 2018 n/a n/a UK£2b
Jun 30 2018 n/a n/a UK£2b
Mar 31 2018 n/a n/a UK£1b
Dec 31 2017 UK£5m UK£965k UK£2b
報酬と市場: Emmaの 総報酬 ($USD 16.16M ) は、 US市場 ($USD 12.67M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Emmaの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。
CEO（最高経営責任者 Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 CEO & Director 7.6yrs UK£12.72m 0.040% $ 28.2m CFO & Executive Director 1.6yrs UK£5.14m 0.0024% $ 1.7m Chief Digital & Technology Officer 3.8yrs データなし データなし Chief Scientific Officer and Head of R&D 2.3yrs データなし データなし Head of Investor Relations no data データなし データなし Senior VP & Group General Counsel of Legal & Compliance 6.3yrs データなし データなし Senior Vice President of Global Communications & CEO Office 5.7yrs データなし データなし President of Corporate Development no data データなし データなし Chief People Officer 5.6yrs データなし データなし President of Global Affairs 7.6yrs データなし 0.0057% $ 4.0m Chief Commercial Officer 7.2yrs データなし データなし Senior VP & Head of Worldwide Business Development for Pharmaceuticals Research Development 6.4yrs データなし データなし
もっと見る
経験豊富な経営陣: GSKの経営陣は経験豊富で 経験豊富 です（平均在職期間は6年）。
取締役 名称 ポジション 在職期間 報酬 所有権 CEO & Director 7.8yrs UK£12.72m 0.040% $ 28.2m CFO & Executive Director 1.5yrs UK£5.14m 0.0024% $ 1.7m Non-Executive Chairman 5.2yrs UK£765.00k 0.0020% $ 1.4m Independent Non-Executive Director 2.3yrs UK£147.00k 0.00036% $ 254.2k Non-Executive Director 6.8yrs UK£356.92k 0.032% $ 22.6m Independent Non-Executive Director 2.8yrs UK£207.09k 0.00016% $ 113.0k Independent Non-Executive Director 3.5yrs UK£174.93k 0.00017% $ 120.0k Independent Non-Executive Director 1.1yrs UK£32.00k 0.000040% $ 28.2k Senior Independent Non-Executive Director 4.5yrs UK£323.00k 0.0014% $ 1.0m Independent Non-Executive Director less than a year データなし 0.000030% $ 21.2k Independent Non-Executive Director 2.2yrs UK£127.86k 0.000090% $ 63.5k Independent Non-Executive Director 8.8yrs UK£173.36k 0.00073% $ 515.4k
もっと見る
経験豊富なボード: GSKの 取締役会 は 経験豊富 であると考えられます ( 3.2年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}